Taken together, our results show that KLK2 is a promising cell surface target for prostate cancer, addressable by a bispecific antibody (KLK2 × CD3), RLT (225Ac-KLK2), and KLK2-targeted CAR T cells. Here, KLK2 is linked to prostate carcinoma.